Ochsner Health is a system that delivers health to the people of Louisiana, Mississippi and the Gulf South with a mission to Serve, Heal, Lead, Educate and Innovate.
We enroll approximately 300 patients annually on NCI NCORP and pharmaceutical industry-sponsored clinical research trials. Our Precision Cancer Therapies Program concentrates on new drug development and Phase 1.
Fellows are expected to complete a clinical research project, perform a quality/performance improvement project, and publish case reports/literature reviews during their fellowship.
Funds are available for fellows to present their research at national meetings.
COVID-19 in Relation to Hematological Events and Mortality in Subset of Inpatient Cancer Patients presented at AACR Virtual Meeting: COVID-19 and Cancer, July 20-22, 2020. (Dr. Gadde)
Outcomes of patients with multiple myeloma with COVID-19 infection presented at AACR Virtual Meeting: COVID-19 and Cancer, July 20-22, 2020. (Dr. Lunski)
Prostate cancer and COVID-19: Impact of hormonal therapy on severe outcomes presented at AACR Virtual Meeting: COVID-19 and Cancer, July 20-22, 2020. (Dr. Tawagi)
Breast Cancer and COVID-19: Impact of Active Treatment on Severe Outcomes accepted for poster presentation at the 2020 San Antonio Breast Cancer Symposium®, December 8-12, 2020. (Dr. Tawagi)
Julia Levy, Fady Farag, John Cole.”Factors influencing the initiation of adjuvant endocrine therapy in patients with estrogen receptor-positive ductal carcinoma in situ: a single institution experience.” Breast Cancer Res Treat. 2022 Nov;196(1):207-213. doi: 10.1007/s10549-022-06735-9. Epub 2022 Sep 9.PMC #9550728
Veronica Mollica , Matteo Santoni , Marc R Matrana, Umberto Basso, Ugo De Giorgi, Alessandro Rizzo, Marco Maruzzo, Andrea Marchetti, Matteo Rosellini, Sara Bleve, Diana Maslov, Karine Tawagi, Ernest Philon, Zoe Blake, Francesco Massari “ Concomitant Proton Pump Inhibitors and Outcome of Patients Treated with Nivolumab Alone or Plus Ipilimumab for Advanced Renal Cell Carcinoma.” Target Oncol. 2022 Jan;17(1):61-68. doi: 10.1007/s11523-021-00861-y. Epub 2021 Dec 11. PMID #34894318
Lunski, Michael J., Jeffrey Burton, Karine Tawagi, Diana Maslov, Victoria Simenson, Daniel Barr, Helen Yuan et al. "Multivariate mortality analyses in COVID‐19: Comparing patients with cancer and patients without cancer in Louisiana." Cancer (2021). PMID #33112411
Maslov, Diana, Karine Tawagi et al. “Timing of Steroid Initiation and Response Rates to Immune Checkpoint Inhibitors in Metastatic Cancer". Submitted to JITC (2021).
Azeem Khan M, Florou V, Swami U. Immunotherapy and fatigue: what we know and what we don't know. Oncotarget. 2021;12(8):719-720. Published 2021 Apr 13. doi:10.18632/oncotarget.27946.
Thu Thu Aung, Andrew Chu, Divya Kondapi, Danny Markabawi, Kanish Mirchia, Pratibha Kaul. “A Case of Pulmonary Epithelioid Hemangioendothelioma with Literature Review.” Case Rep Oncol Med. 2020 Oct 8:2020:8048056. doi:10.1155/2020/8048056. eCollection 2020. PMID #33101745
Boyce, Jessica, Karine Tawagi, and John T. Cole. "Primary colon adenocarcinoma with choriocarcinoma differentiation: a case report and review of the literature." Journal of Medical Case Reports 14, no. 1 (2020): 1-10. PMID #33190644
“Real-world data and racial outcomes for NSCLC in the chemo-immunotherapy era” (Dr. Markabawi) to be presented at 2021 IASLC meeting.
"PD-1/PD-L1/CTLA-4 Inhibitor therapy following progression on a differentPD-1/PD-L1 Inhibitor : a case series." (Dr. Mukamalla) Presented at 2020 SITC.
Clinical outcomes for advanced hepatocellular carcinoma patients treated with systemic agents in real-world practice, first author, poster presentation' (Dr. Tawagi) Presented at 2020 NCCN conference.
Clinical characteristics and outcomes of patients with resectable, metastatic colorectal cancer treated with adjuvant FOLFIRI after progression on neoadjuvant FOLFOX ASCRS Accepted January 24, 2020. (Dr. Luk)
Malignant Mesothelioma and Germline Heterozygous BAP1 Mutation in a Young Woman Presenting with Recurrent Pleural Effusions and Worsening Pneumothorax After Talk Pleurodesis. Accepted CHEST 2020. (Dr. Luk)
Utilization of genomic mutational information in breast cancer patients. (Dr. Gadde)
Interest in adaptive immunotherapies, and immune-related toxicities in solid tumors. (Dr Tawagi)
Involvement in prospective clinical trial looking using regimen to augment standard immunotherapy in melanoma & genitourinary patients. (Dr. Tawagi)
Retrospective study looking at rate of autoimmune flares & irAES in patients with a pre-existing history of autoimmune disease. (Dr. Tawagi)
Abstract Accepted Dr. Tawagi: Timing of steroid doses and response rates to immune-checkpoint inhibitors in metastatic cancer. SITC 35th Anniversary Annual Meeting during SITC 2020, Virtual Poster Hall, 11/11/2020 – 11/14/2020 9a-5p. Abstract ID 247
Abstract Accepted Dr. Mukkamala: PD-1/PD-L1/CTLA-4 inhibitor therapy following progression on a different PD-1/PD-L1 inhibitor: a case series. SITC 35th Anniversary Annual Meeting during SITC 2020, Virtual Poster Hall, 11/11/2020 – 11/14/2020 9a-5p
JMCR-D-20-00712R1 - Primary colon adenocarcinoma with choriocarcinoma differentiation: a case report and review of literature Jessica Boyce, MD; Karine Tawagi, MD; John T Cole, MD - Journal of Medical Case Reports - Accepted for Publication (9/29/20)
Wesley A Duerson, Caitlin E Lopes, Donny A Dumani “Self-limited thrombotic thrombocytopenic purpura.” Blood Coagul Fibrinolysis. 2023 Apr 1;34(3):218-220.doi: 10.1097/MBC.0000000000001188. Epub 2022 Dec 22.. PMID #36728967
Matteo Santoni, Francesco Massari, Enrique Grande, Giuseppe Procopio, Marc R Matrana, Mimma Rizzo, Ugo De Giorgi, Umberto Basso, Michele Milella, Roberto Iacovelli, Gaetano Aurilio, Lorena Incorvaia, Sebastiano Buti, Orazio Caffo, Giuseppe Fornarini, Francesco Carrozza, Veronica Mollica, Alessandro Rizzo, Fady Farag, Javier Molina-Cerrillo, Nicola Battelli “Cabozantinib in Pretreated Patients with Metastatic Renal Cell Carcinoma with Sarcomatoid Differentiation: A Real-World Study.” Target Oncol. 2021 Sep;16(5):625-632.doi: 10.1007/s11523-021-00828-z. Epub 2021 Aug 2.. PMID #34338966
The changing molecular landscape of AML and its impact on treatment. Review Article Integr Mol Med 2020 doi: 10.15761/IMM.1000405. June 30, 2020. Dr. Lunski and Dr. Khan with Drs. Finn, Davis, Staton and Badari.